Form 8-K - Current report:
SEC Accession No. 0001628280-25-021506
Filing Date
2025-05-01
Accepted
2025-05-01 16:00:50
Documents
14
Period of Report
2025-04-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20250425.htm   iXBRL 8-K 36590
2 EX-99.1 ex991pressreleasedatedmay1.htm EX-99.1 10033
  Complete submission text file 0001628280-25-021506.txt   179003

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20250425.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20250425_lab.xml EX-101.LAB 22543
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20250425_pre.xml EX-101.PRE 13047
16 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20250425_htm.xml XML 2829
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 25902823
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)